BIO-TECHNE Corp Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on October 30, 2025, by BIO-TECHNE Corporation (NASDAQ: TECH). The report covers the results of operations for the quarter ended September 30, 2025, and details the outcomes of the Company's Annual Meeting of Shareholders held on November 5, 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing specific results of operations and financial condition data for the quarter ended September 30, 2025. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Additionally, a cash dividend was announced via a separate press release (Exhibit 99.2), though the specific dividend amount is not stated in this document.
Material Changes and Corporate Actions
- Shareholder Voting: A quorum was established with 140,827,559 shares represented (approximately 90.45% of outstanding shares).
- Board Composition: Shareholders voted to set the number of directors at nine.
- Director Elections: All nine nominees were elected to the Board of Directors under a majority voting standard.
- Executive Compensation: Shareholders adopted a non-binding resolution approving the compensation of named executive officers.
- Independent Auditor: Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies within the text provided. Investors are directed to the attached press releases for operational results and dividend details. The filing includes standard disclaimers that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Review Exhibit 99.1 for specific Q3 2025 revenue, earnings, and cash flow figures.
- Review Exhibit 99.2 for the specific amount and payment date of the declared cash dividend.
- Note the high level of shareholder participation (90.45%) and the strong support for director nominees.
- Observe the significant "Against" votes on the executive compensation proposal (approximately 39 million shares against vs. 100 million for).